Samsung Biologics starts IPO process, discloses 2015 revenue and names Benepali as main product 12-Aug-2016 By Gareth Macdonald Samsung Biologics has requested approval to list on the South Korea KOSPI exchange.
Samsung on Samsung: Bioepis selects Biologics as a biosimilars CMO 03-May-2016 By Dan Stanton Samsung Biologics has been contracted by its joint venture entity Samsung Bioepis to manufacturer biosimilars from its facility in Korea.
Samsung Biologics in 10 Year Deal to Make Yervoy MAb for BMS 31-Jul-2013 By Dan Stanton Bristol-Myers Squibb has selected Samsung Biologics to manufacture the antibody cancer drug Yervoy for markets outside the US.
Samsung halts biosimilar rituximab trial on regulatory concerns 18-Oct-2012 By Gareth Macdonald Reports suggest that Samsung Biologics has halted a trial of a biosimilar version of Roche and Biogen Idec's Rituxan (rituximab).
Samsung and Quintiles' biosimilars JV teams with Biogen Idec Samsung and Quintiles' biosimilars JV teams with Biogen Idec 06-Dec-2011 By Gareth Macdonald Samsung will set up a $300m biosimilars development JV with Massachusetts, US-based Biogen Idec, building on the partnership it forged with CRO Quintiles earlier this year.
